Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PEG-glutaminase/diazo-oxo-L-norleucine

Drug Profile

PEG-glutaminase/diazo-oxo-L-norleucine

Alternative Names: Diazo-oxo-L-norleucine/PEG-glutaminase; Diazooxonorleucine/PEG-glutaminase; DON/PEG-PGA; GlutaDON; PEG-glutaminase/diazooxonorleucine; PEG-PGA/DON

Latest Information Update: 16 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator New Medical Enzymes AG
  • Class Antineoplastics; Azo compounds; Glutaminase; Norleucines
  • Mechanism of Action DNA synthesis inhibitors; Glutamine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I/II Gastric cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 16 Jun 2015 Phase-I/II development is ongoing for metastatic colorectal cancer, renal cell carcinoma, non-small cell lung cancer, gastric cancer and other solid tumours in Europe
  • 26 Feb 2013 New Medical Enzymes terminates a phase II trial in Colorectal cancer (metastatic) in Poland (EudraCT2009-017871-13)
  • 01 Feb 2013 Phase-I/II clinical trials in Gastric cancer in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top